Coronary Atherosclerosis T1-Weighted Characterization (CATCH)

Part of paid clinical trials in Los Angeles, California.

Sponsor
Cedars-Sinai Medical Center
Study ID
NCT03504956
Status
Recruiting
Apply to this trial

Conditions

  • Coronary Atherosclerosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Cardiac MRI — DEVICE
    MRI with/without administration of a contrast agent and beta-blocker based upon the stage of method development, if no contraindications are present.
  • Contrast — DRUG
    The intravenous gadolinium based contrast agent to be used in this study is Gadavist (up to 0.2 mmol/kg).
  • Beta blocker — DRUG
    Based upon the focus of the study at the time of the scan, a beta- blocker (metoprolol), in pill form based upon blood pressure and heart rate, may be administered to some subjects to improve the heart's ability to relax and slow the heart rate. The slower heart rate may improve image quality and lessen motion artifact.

Study Details

This study proposes to develop an MRI technique named Coronary Atherosclerosis T1-weighed Characterization (CATCH) that will improve the quality and reliability of coronary atherosclerosis evaluation, as well as simplify the scanning process and significantly shorten imaging time compared with conventional imaging methods.

Key Dates

Start date
Jul 30, 2018
Status verified
Jul 2025
Primary completion
Dec 31, 2025
Completion
Dec 31, 2026

Study Design

Enrollment
150 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Other: Healthy Volunteers
    Approximately 110 healthy male/female adult "normals" or "controls" will receive non-contrast or contrast-enhanced Cardiac MRI. Imaging may include administration of contrast and a beta blocker, based upon the focus of the study at the time of the scan, as well as the safety profile of the participant.
  • Other: Coronary Artery Disease (CAD) Patients
    40 male/female adult outpatients who are suspected of having or have been diagnosed with coronary artery disease (CAD) will receive non-contrast or contrast-enhanced Cardiac MRI. Imaging may include administration of contrast and a beta blocker, based upon the focus of the study at the time of the scan, as well as the safety profile of the participant.

Primary Outcome Measure

Plaque to Myocardial Ratio (PMR). [ Time Frame: Day 1 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Cedars-Sinai Medical CenterLos AngelesCalifornia90048
Rhona Littman
[email protected]
310 423-4387
Debiao Li, PhD
[email protected]
310 423-7743

Find similar trials in Los Angeles, CA

By research site
Cedars-Sinai Medical Center· Los Angeles, CA

Related Studies